Female patient with histopathologically proven ER+ breast cancer.
Diagnosed with locally advanced (primary tumor \>5 cm and/or presence of axillary lymph node metastases) or recurrent breast cancer, or metastatic breast cancer for which 18F-FDG PET/CT or 18F-FDG PET/MRI staging is performed.
Willing and able to undergo the study procedures.
Has personally provided written informed consent.
You may not be if
Age \<18
Pregnancy
Patients with secondary malignancies (except non-melanoma skin cancer)
No 18F-FDG PET/CT or 18F-FDG PET/MRI scan.
Contra-indications for PET/MRI such as pacemaker, aneurysm clips, metallic device in their body, severe claustrophobia, and severe obesity
Chronic inflammatory disease such as rheumatoid arthritis.
Patients with severe hepatic or renal impairment (eGFR ≤45mL/min/1.73m²)
Inability to provide informed consent.
Clareo Health | 18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.
